The latest price target for Ascendis Pharma (NASDAQ:ASND) was reported by RBC Capital on March 3, 2026. The analyst firm set a price target for $275.00 expecting ASND to rise to within 12 months (a possible 21.69% upside). 38 analyst firms have reported ratings in the last year.

The latest analyst rating for Ascendis Pharma (NASDAQ:ASND) was provided by RBC Capital, and Ascendis Pharma maintained their outperform rating.

The last upgrade for Ascendis Pharma AS happened on May 5, 2025 when Morgan Stanley raised their price target to $250. Morgan Stanley previously had an equal-weight for Ascendis Pharma AS.

There is no last downgrade for Ascendis Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ascendis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ascendis Pharma was filed on March 3, 2026 so you should expect the next rating to be made available sometime around March 3, 2027.

While ratings are subjective and will change, the latest Ascendis Pharma (ASND) rating was a maintained with a price target of $250.00 to $275.00. The current price Ascendis Pharma (ASND) is trading at is $225.98, which is out of the analyst’s predicted range.